Cellbricks Therapeutics has secured €10 million in new financing to push its biofabricated tissue implants into rigorous preclinical testing. The round comprises a €7 million seed alongside more than €3 million in non-dilutive funding currently under negotiation. Together, the capital gives the company what it needs to run real experiments, generate real evidence, and take a meaningful step toward clinical use.
The round was led by Silicon Roundabout Ventures, the London-based deep-tech fund known for backing technical founders at the earliest stages. Germany's Federal Agency for Breakthrough Innovation, SPRIND, joined as a non-dilutive contributor, as did existing backer ACT Venture Partners and a group of long-term investors who have supported Cellbricks since its early days.
For patients dealing with severe soft tissue loss, full thickness burns, blast injuries, or reconstructive defects, the options medicine offers today are often a compromise. Invasive grafting procedures, synthetic implants, and other stopgap solutions can restore shape, but they rarely restore function. The tissue does not truly integrate. It does not behave like living biology. Patients and surgeons know this, even when there are no better alternatives.
Regenerative medicine has spent decades promising something different. The field has produced remarkable science, but clinical proof has lagged behind. Moving from a compelling concept to a tissue implant that survives, vascularizes, and integrates in a living body has turned out to be one of the harder problems in modern medicine.
"Regenerative medicine has talked for a long time about what may one day be possible. The next chapter is about demonstrating what can actually work in relevant models, with living tissues designed to integrate, restore function and move with real credibility towards the clinic." — Dr. Simon MacKenzie, Co-CEO, Cellbricks Therapeutics.
The new capital will go directly into execution. Cellbricks Therapeutics plans to launch up to three preclinical animal studies, focused on advancing its lead adipose tissue implant program and generating the translational data required to justify moving into human clinical studies. The immediate clinical focus is on major unmet needs in reconstructive surgery, wound healing, and trauma care, including soft tissue defects and potential alternatives to synthetic breast implants.
But the work being funded today is also building toward something larger. Cellbricks Therapeutics' long-term ambition is 3D-bioprinted viable human organs. The route to that goal is not a single breakthrough moment. It is a methodical, tissue-by-tissue process of solving the biology, the engineering, and the translation challenges that have kept the field stuck for years. Living implants that can survive and function in the body are the necessary groundwork.
"The ambition is clear: restoring functional human tissue and, ultimately, enabling organ replacement. That future is built one disciplined milestone at a time. This funding allows us to reach the next level of validation and to advance living tissue implants that address urgent patient needs now while laying the groundwork for what comes next." — Alexander Leutner, Co-CEO and Co-Founder, Cellbricks Therapeutics.
Cellbricks Therapeutics is a tissue engineering company building biofabricated human tissue implants for regenerative medicine. The company has developed a proprietary biofabrication platform capable of producing vascularized human tissue therapeutics, engineered to restore function in patients with severe tissue damage, including complex wounds and soft tissue defects. Longer-term, the platform is designed with organ repair and replacement in mind.
The company operates across two of the world's most active biotech innovation clusters: Berlin and Boston. This dual presence reflects a deliberate effort to access the scientific talent, regulatory expertise, and investor networks that serious translational development demands.
Cellbricks Therapeutics is advancing a program that requires getting a lot of hard things right at once, from the biology of vascularization to the manufacturing consistency needed for clinical-grade tissue constructs. This round gives it the time and resources to do that work properly.
Silicon Roundabout Ventures led the round. The fund grew out of a London pub meetup into a 15,000-strong community of scientists and engineers, focused exclusively on European deep-tech founders building in areas like computing, energy, and defence.
SPRIND, Germany's Federal Agency for Breakthrough Innovation, contributed non-dilutive funding. Founded in 2019, it invests around €250 million per year in European breakthrough technologies from early development through to market launch.
ACT Venture Partners returned as an existing investor. The European early-stage VC firm specialises in deep-tech startups with team members in Amsterdam, London, and Istanbul. Alongside capital, the firm offers strategic support in fundraising, hiring, and public policy navigation.
